Therapeutic: iruplinalkib as an anticancer agent
The tyrosine kinase receptor ALK (anaplastic lymphoma kinase) has become an important target for cancer therapy; following the approval of crizotinib more than a decade ago, several drugs in various generations of the class are already available for patients